An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said. In an open-label randomized phase II trial, adding the compound -- boceprevir -- to standard therapy in various combinations increased the so-called sustained virological response compared with a control group who got only standard care, according to Paul Kwo, MD, of the Indiana University School of Medicine in Indianapolis, and colleagues.
